Wells Fargo’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-20
| Closed | – | – | 6830 |
|
|
2018
Q4 | $0 | Sell |
20
-18,491
| -100% | -$19.2K | ﹤0.01% | 6903 |
|
|
2018
Q3 | $24K | Sell |
18,511
-7,790
| -30% | -$12.1K | ﹤0.01% | 5795 |
|
|
2018
Q2 | $36K | Sell |
26,301
-30,635
| -54% | -$46.9K | ﹤0.01% | 5688 |
|
|
2018
Q1 | $83K | Buy |
56,936
+28,884
| +103% | +$60.3K | ﹤0.01% | 5385 |
|
|
2017
Q4 | $63K | Sell |
28,052
-16,844
| -38% | -$42.6K | ﹤0.01% | 5479 |
|
|
2017
Q3 | $152K | Sell |
44,896
-10,240
| -19% | -$34.4K | ﹤0.01% | 5053 |
|
|
2017
Q2 | $195K | Buy |
55,136
+12,104
| +28% | +$39.9K | ﹤0.01% | 4805 |
|
|
2017
Q1 | $146K | Buy |
43,032
+15,060
| +54% | +$58.6K | ﹤0.01% | 5004 |
|
|
2016
Q4 | $128K | Buy |
27,972
+20,008
| +251% | +$82.6K | ﹤0.01% | 5024 |
|
|
2016
Q3 | $33K | Buy |
7,964
+7,826
| +5,671% | +$25.3K | ﹤0.01% | 5460 |
|
|
2016
Q2 | $0 | Sell |
138
-754
| -85% | -$2.73K | ﹤0.01% | 6723 |
|
|
2016
Q1 | $4K | Buy |
892
+661
| +286% | +$2.56K | ﹤0.01% | 5948 |
|
|
2015
Q4 | $1K | Buy |
231
+2
| +0.9% | +$9 | ﹤0.01% | 6174 |
|
|
2015
Q3 | $1K | Sell |
229
-464
| -67% | -$2.13K | ﹤0.01% | 6155 |
|
|
2015
Q2 | $3K | Buy |
693
+390
| +129% | +$3.74K | ﹤0.01% | 6144 |
|
|
2015
Q1 | $2K | Sell |
303
-6
| -2% | -$30 | ﹤0.01% | 6023 |
|
|
2014
Q4 | $1K | Buy |
+309
| New | +$1.24K | ﹤0.01% | 6168 |
|
Wells Fargo's AST Position: Q1 2019 in Review
Wells Fargo sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 20 shares.
Wells Fargo first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $195K in Q2 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Wells Fargo reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Wells Fargo sold 20 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- Wells Fargo first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Wells Fargo's Asterias Biotherapeutics Inc. Series A position peaked at $195K in Q2 2017.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Wells Fargo's 13F filing for Q1 2019, filed 10 May 2019.